Roche's Xenical sales probed in U.K.

Could Big Pharma be held to account for gray market sales of its drugs? Take a look at what's happening in the U.K.: Its drug industry watchdog is investigating Roche over its sales of weight-loss med Xenical to private diet clinics. At issue, apparently, is a marketing relationship Roche had with the operator of one large chain of clinics; drugs sold to the clinics may have been resold under the table.

The Prescription Medicines Code of Practice Authority--a mouthful of a name for the pharma industry's regulatory body--says it's opened a probe into "alleged inducement and supply of Xenical." The investigation comes on the heels of a) a lawsuit filed by an ex-Roche regulatory affairs chief and b) reporting in the Financial Times on some internal Roche documents filed as part of that ex-employee's legal complaint. Those documents outlined the relationship between Roche and Robin Huxley, the diet-chain operator who bought large amounts of Xenical over a two-year period.

Roche has denied wrongdoing, saying that it has conducted its own internal audits of its deals with Huxley.

- read the news in the Financial Times

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.